Molecular therapy of breast cancer: Progress and future directions

Nature Reviews Endocrinology

Volumn 6, Issue 9, 2010, Pages 485-493

  Lin, Sheng Xiang ^a   Chen, Jiong ^b   Mazumdar, Mausumi ^a   Poirier, Donald ^a   Wang, Cheng ^c   Azzi, Arezki ^a   Zhou, Ming ^a  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c Central Hospital of Huangpu District   (China)

Author keywords

[No Author keywords available]

Indexed keywords

667 COUMATE; ANASTROZOLE; AROMATASE INHIBITOR; CANCER VACCINE; COUMARIN DERIVATIVE; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTERASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; IMATINIB; LETROZOLE; NILOTINIB; OXIDOREDUCTASE INHIBITOR; PACLITAXEL; PERTUZUMAB; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SORAFENIB; STERYL SULFATASE; STERYL SULFATASE INHIBITOR; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER GENE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RECEPTOR BINDING; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; FRACTURE; HOT FLUSH; HUMAN; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL DISEASE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77955923386     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.92     Document Type: Review

References (112)

1. WHO. Breast cancer burden [online], http:// www.who.int/cancer/detection/ breastcancer/ en/index1.html
2. National Cancer Institute. Probability of breast cancer in American women [online], http:// www.cancer.gov/cancertopics/factsheet/ Detection/probability- breast-cancer
3. American Cancer Society. Breast cancer facts and figures 2009-2010 [online], http:// www.cancer.org/downloads/STT/F861009- final%209-08-09.pdf
4. American Cancer Society. What are the key statistics about lung cancer [online], http:// www.cancer.org/docroot/cri/content/ cri-2-4-1x-what-are-the- key-Statistics-about- lung-cancer-15.asp.
5. Jonat, W. et al. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J. Cancer Res. Clin. Oncol. 132, 275-286 (2006).
6. Myutan, K., Mohamed, S. & Kefah, M. Estrogensynthesising enzymes and breast cancer. Anticancer Res. 29, 1095-1109 (2009).
7. Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502 (2006).
8. Labrie, F. Intracrinology. Mol. Cell Endocrinol. 78, C113-C118 (1991).
9. Harada, N. Aromatase and intracrinology of estrogen in hormone-dependent tumors. Oncology 57, 7-16 (1999).
10. Labrie, F. Extragonadal synthesis of sex steroids: intracrinology. Ann. Endocrinol. (Paris) 64, 95-107 (2003).
11. Sasano, H. et al. New development in intracrinology of breast carcinoma. Breast Cancer 13, 129-136 (2006).
12. Rose-Hellekant, T. A. et al. Short-term prophylactic tamoxifen reduces the incidence of antiestrogenresistant/ estrogen receptor-positive/ progesterone receptor-negative mammary tumors. Cancer Prev. Res. (Phila Pa) 2, 496-502 (2009).
13. Leung, F. P. et al. Raloxifene, tamoxifen and vascular tone. Clin. Exp. Pharmacol. Physiol. 34, 809-813 (2007).
14. Ohta, H. Selective estrogen receptor modulator. Clin. Calcium 14, 165-172 (2004).
15. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60 (2005).
16. Schwartz, L. M. et al. The drug facts box: providing consumers with simple tabular data on drug benefit and harm. Med. Decis. Making 27, 655-662 (2007).
17. Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
18. Duggan, C. et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J. Clin. Oncol. 21, 3588-3593 (2003).
19. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
20. Fisher, B. et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320, 479-484 (1989). (Pubitemid 19062522)
21. Bergman, L. et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356, 881-887 (2000).
22. Fisher, B. et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
23. Bonneterre, J. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J. Clin. Oncol. 18, 3748-3757 (2000).
24. Barry, M. & Malcolm, R. K. Enhancing the adjuvant treatment of hormone receptor positive breast cancer. Breast J. 15, 194-198 (2009).
25. Kudachadkar, R. & O'Regan, R. M. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J. Clin. 55, 145-163 (2005).
26. Cummings, S. R. et al. The effect of raloxifen on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 281, 2189-2197 (1999).
27. Manni, A. Clinical use of aromatase inhibitors in the treatment of breast cancers, J. Cell Biochem. Suppl. 17g, 242-246 (1993).
28. Iveson, T. J. et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 53, 266-270 (1993).
29. Geisler, J. et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma extrogen levels. Cancer Therapy: Clinical 14, 6330-6335 (2008).
30. Cuzick, J. Aromatase inhibitors for breast cancer prevention. J. Clin. Oncol. 23, 1636-1643 (2005).
31. Mauriac, L. et al. BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann. Oncol. 18, 859-867 (2007).
32. Coates, A. S. et al. Five years of letrozole compared with tamoxifen as initial therapy of postmenopausal women with endocrineresponsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-493 (2007).
33. Santner, S. J. et al. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59, 29-33 (1984).
34. Joerger, M. & Thürlimann, B. Update of the BIG 1-98 Trial: where do we stand. Breast 18 (Suppl. 3), S78-S82 (2009).
35. Harbeck, N. & Jakesz, R. St. Gallen: Breast cancer treatment consensus report. Breast Care 2, 130-134 (2007).
36. ATAC Trialists Group. Effects of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet 9, 45-53 (2008).
37. Mayor, S. NICE updates guidance on early and advanced breast cancer. BMJ 338, b815 (2009).
38. Dunn, B. K. & Ryan, A. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators, Ann. NY Acad. Sci. 1155, 141-161 (2009).
39. Ghosh, D. et al. Structural basis for androgen specificity and estrogen synthesis in human aromatase. Nature 457, 219-223 (2009).
40. Pasqualini, J. R. et al. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34, 155-163 (1989).
41. Miller, W. R. Aromatase and the breast: regulation and clinical aspects. Maturitas 54, 335-341 (2006).
42. Bonney, R. C. et al. The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumors and in normal breast tissue. Clin. Endocrinol. 19, 727-739 (1983).
43. Bhatngar, A. S. The discovery and mechanism of action of letrozole. Breast Cancer Res. Treat. 105, 7-17 (2007).
44. Miyoshi, Y. et al. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 94, 685-689 (2001).
45. Suzuki, T. & Sasano, H. In situ production of sex steroids in human breast carcinoma. Med. Mol. Morphol. 40, 121-127 (2007).
46. Evans, T. R. et al. Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. Br. J. Cancer 69, 555-561 (1994).
47. Lonning, P. E., Dowsett, M. & Powles, T. J. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. J. Steroid Biochem. 35, 355-366 (1990).
48. Poulin, R. & Labrie, F. Stimulation of cell proliferation and estrogen response by adrenal C-19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. 46, 4933-4937 (1986).
49. Stanway, S. J. et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12, 1585-1592 (2006).
50. Ciobanu, L. C. et al. Potent inhibition of steroid sulfatase activity by 3-O-sulfamate-17alpha benzyl (or 4'-tert-butyl-benzyl) estra-1, 3, 5(10)-trienes: combinations of two substituents at position C3 and C17alpha of estradiol. J. Med. Chem. 42, 2280-2286 (1999).
51. Woo, L. W. L. et al. Dual aromatase-steroid sulfatase inhibitors. J. Med. Chem. 50, 3540-3560 (2007).
52. Day, J. M. et al. The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann. NY Acad. Sci. 1155, 80-87 (2009).
53. Foster, P. A. et al. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clin. Cancer Res. 14, 6469 (2008).
54. Stanway, S. J. et al. Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist 12, 370-374 (2007).
55. Hernandez-Guzman, F. G. et al. Structure of human estrone sulfatase suggests functional roles of membrane association. J. Biol. Chem. 278, 22989-22997 (2003).
56. Jin, J. Z. & Lin, S. X. Human estrogenic 17betahydroxysteroid dehydrogenase: predominence of estrone reduction and its induction by NADPH. Biochem. Biophys. Res. Commun. 259, 489-493 (1999).
57. Gunnarsson, C. et al. Southeast Sweden Breast Cancer Group. Abnormal expression of 17betahydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res. 61, 8448-8451 (2001).
58. Oduwole, O. O. et al. 17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res. 15, 7604-7609 (2004).
59. Husen, B. et al. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 147, 5333-5339 (2006).
60. Ghosh, D. et al. Structure of human 17-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 3, 503-513 (1995).
61. Gangloff, A. et al. Pseudo-symmetry of C19-steroids, alternative binding orientations, and multispecificity in human estrogenic 17-hydroxysteroid dehydrogenase. FASEB J. 17, 274-276 (2003).
62. Qiu, W. & Lin, S.-X. A concerted, rational design of 17-hydroxysteroid dehydrogenase inhibitors: complex structure with estradiol-adenosine hybrids with high affinity. FASEB J. 16, 1829-1831 (2002).
63. Laplante, Y. et al. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg. Med. Chem. 16, 1849-1860 (2008).
64. Day, J. M. et al. 17beta-hydroxysteroid dehydrogenase type 1, and not type 12, is a target for endocrine therapy of hormonedependent breast cancer. Int. J. Cancer 122, 1931-1940 (2008).
65. Frotscher, M. et al. Design, synthesis, and biological evaluation of (hydroxyphenyl) naphthalene and quinoline derivatives: potent and selective nonsteroidal inhibitors of 17betahydroxysteroid dehydrogenase type 1(17beta-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 51, 2158-2169 (2008). (Pubitemid 351503271)
66. Schuster, D. et al. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J. Med. Chem. 51, 4188-4199 (2008).
67. Poirier, D. Advance in development of inhibitors of 17-hydroxysteroid dehydrogenases. Anti-Cancer Med. Chem. 9, 642-660 (2009).
68. Hugh, J. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J. Clin. Oncol. 27, 1168-1176 (2009).
69. Rakha, E. A. & Ellis, I. O. Triple-negative/basallike breast cancer: review. Pathology 41, 40-47 (2009).
70. Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Basallike breast cancer: A critical review. J. Clin. Oncol. 26, 2568-2581 (2008).
71. Collett, K. et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev. 14, 1108-1113 (2005).
72. Jones, C. et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br. J. Cancer 85, 422-427 (2001).
73. Jumppanen, M. et al. Basal-like phenotype is not associated with patient survival in estrogenreceptornegative breast cancers. Breast Cancer Res. 9, R16 (2007).
74. Bauer, K. R. et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triplenegative phenotype: a population-based study from the California cancer registry. Cancer 109, 1721-1728 (2007).
75. Weigelt, B. et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216, 141-150 (2008).
76. Diallo-Danebrock, R. et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dosedense chemotherapy. Clin. Cancer Res. 13, 488-497 (2007).
77. Simon, R. et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin. Cancer Res. 10, 178-183 (2004).
78. Finn, R. S. et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basaltype/ triple-negative breast cancer cell lines growing in vitro. Breast Cancer Res. Treat. 105, 319-326 (2007).
79. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
80. Gluz, O. et al, Triple-negative breast cancer-current status and future directions. Ann. Oncol. 20, 1913-1927 (2009).
81. Schechter, A. L. et al. The neu oncogene: an erb-B-related gene encoding a 185, 000-Mr tumour antigen. Nature 312, 513-516 (1984).
82. Beckhardt, R. N. et al. HER-2/neu oncogene characterization in head and neck squamouscell carcinoma. Arch. Otolaryngol. Head Neck Surg. 121, 21265-21270 (1995).
83. Menard, S. et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann. Oncol. 12, S15-S19 (2001).
84. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783 (2001).
85. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
86. Gonzalez-Angulo, A. M., Hortobágyi, G. N. & Esteva, F. J. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11, 857-867 (2006).
87. Bedard, P. L., de Azambuja, E. & Cardoso, F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr. Cancer Drug Target 9, 148-162 (2009).
88. Bossenmaier, B. et al. Presence of HER2/HER3 heterodimers predicts antitumor effects of pertuzumab (Omnitarg) in different human xenograft models. Proc. Amer. Assoc. Cancer Res. 45, Abstract #5342 (2004).
89. Mittendorf, E. A. & Peoples, G. E. HER-2/neu peptide breast cancer vaccines: current status and future directions. Breast Diseases: A Year Book Quarterly 17, 318-320 (2007).
90. He, Y. et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine 24, 2575-2584 (2006).
91. Morse, M. A. et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. J. Transl. Med. 5, 42-50 (2007).
92. Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114 (2000).
93. Agrawal, A. et al. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer 12, S135-S144 (2005).
94. Anderson, N. G. et al. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 94, 774-782 (2001).
95. Gutteridge, E. et al. The effects of gefitinib in tamoxifen resistant and hormone insensitive breast cancer: A phase II study. Int. J. Cancer 126, 1806-1816 (2009).
96. Byrns, M. C. et al. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer, J. Steroid Biochem. Mol. Biol. 118, 177-187 (2010).
97. Mattie, M. D. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biospies. Mol. Cancer 5, 24 (2006).
98. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
99. Ramasamy, S. et al. The MUC1 and galecin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol. Cell 27, 992-1004 (2007).
100. Brian, D. A., Irene, K. G. & Bruce, A. White. Involvement of microRNAs in breast cancer. Semin. Reprod. Med. 6, 522-536 (2008).
101. Scott, G. K. et al. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479-1486 (2007).
102. Si, M. L. et al. miR-21-mediated tumor growth. Oncogene 26, 2799-2803 (2007).
103. Kameda, C. et al. The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer. Anticancer Res. 29, 871-879 (2009).
104. Finkbeiner, M. R. et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28, 1421-1431 (2009).
105. Buzdar, A. U. Role of biologic therapy and chemotherapy in hormone receptor-and HER2-positive breast cancer. Ann. Oncol. 20, 993-999 (2009).
106. Fagan, D. H. & Yee, D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 423-429 (2008).
107. Jin, Q. & Esteva F. J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 485-498 (2008).
108. Macedo, L. F., Sabnis, G. & Brodie, A. Aromatase inhibitors and breast cancer. Ann. NY Acad. Sci. 1155, 162-173 (2009).
109. Pegram, M. et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor (VEGF) using trastuzumab and bevacizumab as first-line treatment of HER2 amplified breast cancer. Breast Cancer Res. Treat. 100, 201 (2006).
110. Foulkes, W. D. et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53t/ glomeruloid-microvascular-proliferationt) phenotype of BRCA1-related breast cancer. Cancer Res. 64, 830-835 (2004).
111. Cardoso, P. et al. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008).
112. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).